Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

NCT00770601 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

NOMID
CINCA Syndrome

Interventions

DRUG: Canakinumab

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]